Coert J. Zuurbier
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications
NLRX1 emerges as the only observed essential regulator of the mPTP, challenging mPTP inhibition as a valid target of cardioprotection.
Journal: Basic research in cardiology
Published: May 12, 2026
Unravelling mitochondrial succinate transport during I/R and devising a novel transport inhibitor show promise for targeting I/R injury, but will efficacy remain under more human-like conditions present during I/R?
Journal: Cardiovascular research
Published: March 17, 2026
Metabolic dependency of malonate protection against cardiac ischemia-reperfusion injury.
Journal: Basic research in cardiology
Published: November 24, 2025
Correction: IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning.
Journal: Basic research in cardiology
Published: November 10, 2025
The early metabolic cardiac targets of empagliflozin during the development of heart failure, independent of SGLT2 inhibition.
Journal: Metabolism: clinical and experimental
Published: September 19, 2025
Sodium glucose co-transporter 2 inhibitor empagliflozin prevents endothelial dysfunction induced by oscillatory shear stress.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 30, 2025
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.
Journal: Nature reviews. Cardiology
Published: May 01, 2025
Cardiovascular Outcomes of Perioperative Sodium-Glucose Transporter 2 Inhibition in Cardiac Surgery Patients: An Open-Label Randomized Pilot Study.
Journal: Acta anaesthesiologica Scandinavica
Published: April 15, 2025
Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.
Journal: Cardiovascular research
Published: April 11, 2025
Is boosting OXPHOS/FAO gene pathways the final end-mechanism of SGLT2i protection?
Journal: Journal of molecular and cellular cardiology plus
Published: February 26, 2025
Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 23, 2024
Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium.
Journal: Basic research in cardiology
Published: November 18, 2024
Last Updated: 09/26/2026